KNSA Kiniksa Pharmaceuticals (KNSA) Q2 FY26 earnings call
Kiniksa Pharmaceuticals delivered a strong second quarter, driven by robust commercial execution for ARCALYST, which saw significant revenue growth and increased patient enrollment. The company also advanced its pipeline with the initiation of the KPL-387 Phase III trial for recurrent pericarditis, following positive Phase II data. With a solid financial position and continued pipeline progress, Kiniksa is well-positioned for future value creation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
KNSA operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Prescribers | 4,150+At the end of 2025, more than 4,150 prescribers had written a prescription for ARCALYST.Source: earnings call transcript | — | 5,000+Approximately 450 additional health care professionals wrote their first ARCALYST prescription in the second quarter, bringing the total prescriber base to more than 5,000 launch to date.Source: earnings call transcript | — |
| Repeat prescribers | 1,200+Of those, around 29% or more than 1,200 prescribers have written ARCALYST for 2 or more recurrent pericarditis patients.Source: earnings call transcript | ~1,320We also saw growth in the number of health care professionals who became repeat prescribers during Q1, resulting in approximately 1,320 prescribers in total who have now prescribed ARCALYST multiple times.Source: earnings call transcript | — | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.